Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Morning! Today, a handful of STAT reporters pore through former President Trump’s own remarks over the past year or so to get a sense of his health care agenda. Also, we learn the new priority in CRISPR therapies is delivery, and more.
The need-to-know this morning
- Eli Lilly boosted 2024 revenue guidance by $3 billion on strong Mounjaro, Zepbound sales.
- Apellis Pharmaceuticals announced positive results from a Phase 3 study of its approved drug Empaveli in patients with two types of rare kidney disease. The company plans to seek FDA approval in early 2025. Its marketing partner Sobi will also apply for European approval next year.
- Merck halted a Phase 3 clinical trial of its anti-TIGIT drug vibostolimab in small cell lung cancer after independent monitors determined the drug combined with Keytruda would not prolong patient survival compared to standard treatment.
Trump’s real health care agenda isn’t in Project 2025 — it’s in his own words
Former President Trump has sought to distance himself from Project 2025 — despite efforts by Democrats to link him to the Heritage Foundation plan. So STAT dove deep into Trump’s own remarks on health care issues, taken from his “Agenda47” series and campaign statements, to better understand the policies he might advance if he reclaims the White House.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect